Searched for
BIOCON MANUFACTURING FACILITY
Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps downBiocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...
- Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classificationBiocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classific...
- Biocon inaugurates first manufacturing facility in USBiocon Ltd has inaugurated its first US manufacturing facility in Cranbury, New Jersey, operated by its subsidiary, Biocon Generics Inc. Fo...
- Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plantBiocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patient...
- Biocon acquires Eywa Pharma's US-based plant for $7.7 millionBiocon Limited announced that its wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufact...
- Biocon Biologics gets eight observations from USFDA for Malaysia insulin facilityThe US drug regulator issued 6 observations for drug substance, drug product units and quality Control laboratories and 2 observations for ...
- Biocon Biologics gets EU GMP certification from Ireland's HPRAThe company's new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru has received the certif...
- Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
- Biocon's arm gets GMP compliance certificate from UK's health regulator MHRA for Bengaluru facilityThe certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, wa...
- Biocon shares fall as USFDA issues Form 483 for Bengaluru facilityBiocon said that the observations are procedural in nature.
- Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licenceThis additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its...
- Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facilityThe integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...
- USFDA completes Biocon's Telangana plant inspectionThe inspection was concluded without any observations and no Form 483 was issued, the company said.
- Biocon's insulin facility in Malaysia clears inspections for European marketThe facility, set up with an investment of $275 million, is designed to manufacture recombinant human insulin and insulin analogs for the g...
- Biocon bags Rs 460-crore contract from MalaysiaThe drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...
- Malaysian facility to be commercialised in H2 FY17: BioconInitially, the products from the facility will cater to local markets but they would be taken gradually to global markets, Kiran Mazumdar-S...
Load More
